Celldex Therapeutics, Inc.
CLDX
Positions held
Your positionsCLDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Celldex Therapeutics is positioned in the biotechnology industry, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- The company's target mean price is $63.07, indicating a substantial upside potential from its current trading levels.
- Celldex has a current ratio of 11.82, suggesting a strong liquidity position to cover short-term obligations.
- The biotechnology sector is highly competitive, and Celldex faces challenges in maintaining its market position amidst evolving industry dynamics.
- Revenue decreased by 0.97% year-over-year, reflecting ongoing struggles in generating consistent income.
- The company's operating margin remains significantly negative at -36.65%, indicating ongoing operational inefficiencies.
Fundamentals
| Market cap | $2.30B | Enterprise value | $1.59B | Trailing P/E | — | Forward P/E | -6.92 |
| PEG | — | Price / book | 3.22 | Beta | 0.90 | Dividend yield | 0.00% |
| Revenue growth | -97.0% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -3664.7% |
| Profit margin | 0.0% | ROE | -43.9% | ROA | -27.6% | Debt / equity | 0.01 |
| Current ratio | 11.82 | Free cash flow | -$133.08M | Analyst recommendation | strong_buy | Mean target | $63.07 |
| 52w high | $45.14 | 52w low | $22.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.1M | $0.0M | $0.7M |
| Op margin | -366468.2% | -562900.0% | -72027.3% | — | -8747.5% |
| Net income | -$73.5M | -$78.7M | -$81.3M | -$67.0M | -$56.6M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$80.6M | -$84.4M | -$87.2M | -$73.6M | -$63.9M |
- Revenue +47% vs prior quarter ($0.0M vs $0.0M).
- Operating margin expanded to -366468.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | — |
| Op margin | -18599.8% | -2778.9% | -2063.7% | -4543.7% | — |
| Net income | -$259M | -$158M | -$141M | -$112M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$287M | -$195M | -$142M | -$107M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
2026-09-23 · The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
2026-09-22 · Top Midday Decliners
2026-09-22 · CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
2026-09-22 · Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
2026-09-22 · 4 Biotech Stocks With Key Clinical Readouts Expected This Fall
2026-09-22 · Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
2026-09-22 · Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
2026-09-08 · Celldex to Present at Upcoming Investor Conference
2026-08-09 · Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
2026-08-09 · Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?
Price (daily)
Full chart · RSI · MACD · patterns